(RTTNews.com) - The following are some of today's top gainers in the pharma/biotech sector.
1. Soleno Therapeutics Inc. (SLNO)
The Company is developing therapeutics for the treatment of rare diseases.
Gained 19.58% to close Monday's (Oct.22) trading at $2.26.
News: No news
The lead drug candidate is Diazoxide Choline Controlled-Release (DCCR), under phase III testing for the treatment of Prader-Willi Syndrome.
2. Aratana Therapeutics Inc. (PETX)
Aratana is a pet therapeutics company.
Gained 13.06% to close Monday's trading at $6.06.
News: The Company announced that it will host a live conference call on Friday, November 2, 2018 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2018.
For the second quarter ended June 30, 2018, net loss was $6.4 million or $0.14 per share on revenue of $4.9 million. This compared to a net loss of $10.4 million or $0.26 per share and revenue of $5.2 million in the second quarter of 2017.
3. Enzo Biochem Inc. (ENZ)
Enzo Biochem is an integrated diagnostic and therapeutics company.
Gained 11.59% to close Monday's trading at $3.66.
News: No news
-- On October 15, the Company reported results for the fourth quarter and fiscal year ended July 31, 2018.
The GAAP and Non-GAAP net loss in the recent fourth quarter was $5.8 million or $0.15 per share on total revenues of $24.5 million. This compared to a breakeven on total revenues of $28.2 million in the prior year quarter.
-- On August 27, the Company inked a deal to purchase a commercial facility with nearly 36,000 square feet in Farmingdale, NY, to advance its diagnostic and therapeutic growth strategy.
4. T2 Biosystems Inc. (TTOO)
T2 Biosystems is focused on developing innovative medical diagnostic products for critical unmet needs in healthcare.
Gained 11.39% to close Monday's trading at $5.28.
News: No news
-- On August 2, the Company reported financial results for the second quarter ended June 30, 2018.
Net loss narrowed to $12.32 million or $0.32 per share from $15.45 million or $0.50 per share in the year-ago quarter. Total revenue for the recent second quarter was $3.93 million compared to $956 thousand in the year-ago quarter.
The Company is slated to release its 2018 third quarter financial and operational results after the market closes on Thursday, November 1, 2018.
5. OncoSec Medical Inc.(ONCS)
OncoSec Medical is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies for cancer.
Gained 11.18% to close Monday's trading at $1.79.
News: No news
On October 15, the Company initiated a phase II clinical trial of TAVO, its lead immunotherapy platform, in combination with Merck's KEYTRUDA for the treatment of late-stage triple negative breast cancer. This study, dubbed KEYNOTE-890, marks the second phase II trial for OncoSec involving a combination of TAVO and KEYTRUDA.
The first, PISCES/KEYNOTE-695, is a phase II trial of TAVO in combination with KEYTRUDA for metastatic melanoma.
6. CollPlant Holdings Ltd. ( CLGN )
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets.
Gained 11.09% to close Monday's trading at $6.11.
News: The Company has entered into a license, development and commercialization agreement with United Therapeutics Corp. (UTHR) for 3D bioprinted lung transplants.
As per the deal terms, CollPlant has granted United Therapeutics an exclusive license to its technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants throughout the universe. In turn, CollPlant will receive an upfront payment of $5 million and up to $15 million of milestone payments.
The agreement also provides for option exercise payments of up to $9 million, and additional developmental milestone payments of up to $15 million if United Therapeutics elects to develop manufactured organs other than lungs using CollPlant's technology.
7. Dynavax Technologies Corp. (DVAX)
Gained 11.02% to close Monday's trading at $12.09.
News: On October 20 (Saturday), the Company announced that interim data from its ongoing phase Ib/II study investigating SD-101 in combination with Merck's (MRK) KEYTRUDA, an anti-PD-1 therapy, in patients with advanced melanoma naÃ¯ve to anti-PD-1/L1 therapy were promising.
In the study, dubbed SYNERGY-001, two different doses of SD-101 were tested - less than or equal to 2mg of SD-101 in 1-4 lesions and 8 mg in a single lesion.
The results showed a 70% overall response rate (ORR) in advanced melanoma patients naÃ¯ve to anti-PD-1/L1 therapy who received the less than or equal to 2 mg dose of SD-101, and a 48% ORR in the group receiving the 8 mg dose of SD-101.
The combination of SD-101 and KEYTRUDA remains well tolerated with adverse events related to SD-101 being transient, mild to moderate flu-like symptoms, added the Company.
Read the original article on RTTNews (http://www.rttnews.com/2945993/petx-on-the-move-ttoo-to-report-q3-results-on-nov-1-clgn-inks-deal-with-uthr.aspx)
For comments and feedback: contact firstname.lastname@example.org